Unique ID issued by UMIN | UMIN000010088 |
---|---|
Receipt number | R000011817 |
Scientific Title | Phase II study of Gemcitabine plus alternate-day administrations of S-1 in patients with unresectable advanced pancreatic cancer. |
Date of disclosure of the study information | 2013/02/21 |
Last modified on | 2013/02/21 09:27:56 |
Phase II study of Gemcitabine plus alternate-day administrations of S-1 in patients with unresectable advanced pancreatic cancer.
Phase II study of GEM + alternate-day S-1 treatment for pancreatic cancer.
Phase II study of Gemcitabine plus alternate-day administrations of S-1 in patients with unresectable advanced pancreatic cancer.
Phase II study of GEM + alternate-day S-1 treatment for pancreatic cancer.
Japan |
pancreatic cancer
Hepato-biliary-pancreatic surgery |
Malignancy
NO
To evaluate the efficacy and safety of Gemcitabine plus alternate-day administrations of S-1 in patients with advanced unresectable pancreatic cancer.
Efficacy
Exploratory
Phase II
Response Rate
Overall Survival
Progression-free Survival
Disease Control Rate
Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
GEM 1,000mg/m2 day1
TS-1 50-120mg/day alternate-day (Mondays, Wednesdays, Fridays and Sundays)
q2W
20 | years-old | <= |
Not applicable |
Male and Female
(1)Either histologically or cytologically confirmed adenocarcinoma and adenosquamous carcinoma. Or radiologically confirmed pancreatic cancer.
(2)Unresectable pancreatic cancer (including locally advanced or metastatic pancreatic cancer).
(3)Patients with no previous treatment (radiotherapy, chemotherapy etc) for pancreatic cancer, except resection.
Palliative bypass operation and biliary stent will be permitted.
Intra-operative radiotherapy during resection of pancreatic cancer will be permitted, although registration must be done at least 4 weeks after the radiotherapy.
Patients who have undergone preoperative/postoperative adjuvant chemotherapy can be enrolled if relapse is diagnosed beyond 24 weeks (168days) after the final administration.
(4)Patients with measurable lesions
(5)Age of 20 years or older.
(6)ECOG Performance Status (PS) of 0 or 1.
(7)Adequate major organ functions within 14 days before registration, as defined below:
White blood cell count >= 3500/mm3
Neutrophil count >= 2000/mm3
Hemoglobin >= 9.0 g/dL
Platelet count >= 100,000/mm3
Total bilirubin <= 2.0 mg/dL*
*3.0 mg/dL in patients treated by biliary drainage for obstructive jaundice.
AST and ALT <= 150 U/L
Serum creatinine <= 1.2 mg/dL
Creatinine clearance <= 50mL/min.
(8) Sufficient oral intake.
(9) No clinically abnormal ECG findings within 28 days (4 weeks) before registration.
(10) Patients must have signed an informed consent document.
(1) Contraindication of Gemsitabine and S-1.
(2) Pulmonary fibrosis or interstitial pneumonia (to be confirmed by chest X-ray within 28 days before registration).
(3)Watery diarrhea.
(4)Active infections (e.g. patients with pyrexia of 38 degree centigrade or greater), excluding viral hepatitis.
(5)Serious complications (e.g. heart failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, intestinal paralysis, intestinal obstruction or poorly controlled diabetes).
(6)Moderate or severe (requiring drainage) ascites or pleural effusion requiring treatment.
(7) Metastasis in the CNS.
(8) Active double cancer (synchronous double cancer or asynchronous double cancer with disease-free duration of 3 years or less). Carcinoma in situ and lesions of intramucosal carcinoma will not be included in active double cancer and will be permitted for registration.
(9) Current use of flucytosine, phenytoin or warfarin potassium.
(10) For female subject: Positive Pregnancy test, presently breast feeding or unwilling to use effective contraceptive measure. For male subjects: intent to procreate during the duration of the study or unwilling to use effective contraceptive measure.
(11) Severe mental disorder.
(12) Severe drug allergies.
(13)Decision of not eligible determined by principle investigator or attending doctor.
30
1st name | |
Middle name | |
Last name | Mitsukazu Gotoh |
Fukushima Medical University, School of medicine
Department of Regenerative Surgery
1 Hikariga-oka, Fukushima City, Fukushima Prefecture 960-1295 JAPAN
1st name | |
Middle name | |
Last name | Takao Tsuchiya |
Fukushima Medical University Hospital, School of medicine
Department of Regenerative Surgery
1 Hikariga-oka, Fukushima City, Fukushima Prefecture 960-1295 JAPAN
024-547-1111
Fukushima medical University Hospital, School of medicine
None
Self funding
NO
2013 | Year | 02 | Month | 21 | Day |
Unpublished
Open public recruiting
2012 | Year | 12 | Month | 10 | Day |
2013 | Year | 02 | Month | 01 | Day |
2013 | Year | 02 | Month | 21 | Day |
2013 | Year | 02 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011817
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |